GLAXF News and Press, GlaxoSmithKline Plc From 10/09/23

2023-10-09 13:48:03 ET Summary Innoviva, Inc. is a biopharma company focused on the development and commercialization of pharmaceutical products. However, the company's main asset is royalty revenues that come from products it receives from Glaxo Group Limited. There has been ...

2023-09-29 14:27:37 ET Summary GSK is a leading biopharmaceutical company with a focus on vaccines and products for major diseases. GSK's drug line-up is safe and profitable, with competitors facing larger sales loss exposure due to patent expirations. GSK has a strong balance...

2023-09-22 12:14:52 ET Summary Despite the increasing number of emerging challenges for the pharmaceutical industry, the management teams at GSK and Merck are successfully coping with them. GSK's revenue was $9.12 billion in the second quarter of 2023, up 8.1% year-over-year, beat...

2023-09-21 14:55:48 ET Summary Analysts have soured on Moderna's prospects, despite recent good news in its drug pipeline. This put spread strategy risks $4.53 to make $0.47 in 121 days. The full premium is earned if MRNA remains above $75 on January 19th, 2024. ...

2023-09-19 14:45:33 ET Summary Regeneron Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Tarrytown that has played a key role in the fight against COVID-19. Regeneron's revenue for the second quarter of 2023 was $3.16 billion, an increase of 10.5% compared to th...

2023-09-15 13:02:18 ET Summary Currently, the S&P 500 and many sectors are outperforming the healthcare sector, presenting an opportunity to explore assets within this sector during the current period of apathy towards it. AstraZeneca's revenue was $11.42 billion in the second...

2023-09-14 07:29:05 ET GSK plc (GSK) BofA Global Healthcare Conference September 14, 2023 04:05 AM ET Company Participants Emma Walmsley - Chief Executive Officer Julie Brown - Chief Financial Officer Conference Call Participants Graham Parry - Bank of Am...

2023-09-11 11:49:04 ET Summary Bayer's stock has had a volatile performance, reaching highs and lows since December 2022, when I first wrote about this company. Both from a relative and intrinsic standpoint, Bayer seems to be severely undervalued. Bayer has both short-ter...

2023-09-09 03:17:14 ET Summary Wall Street underestimates the prospects of Pfizer and Gilead Sciences, given their significant role in developing vaccines and medicines against COVID-19. Gilead Sciences' revenue has remained stable in recent quarters, unlike Pfizer, whose demand f...

2023-09-07 12:59:08 ET GSK plc (GSK) Citi's 18th Annual BioPharma Conference September 07, 2023 08:50 A.M. ET Company Participants Phil Dormitzer - SVP, Head of Vaccines R&D Conference Call Participants Andrew Baum - Citi Presentation Andrew...